dm+d

Unassigned

New Medicines

Antiplatelet reversal for patients taking ticagrelor

Information

New molecular entity
PhaseBio
PhaseBio

Development and Regulatory status

None
None
Phase III Clinical Trials

Category

A neutralising antibody that binds to Brilinta/Brilique (ticagrelor) and AR-C124910XX, the ticagrelor active metabolite.
A Cochrane review showed that continuing or stopping antiplatelets may make little or no difference to the number of people who died up to 30 days or six months after surgery (5 studies, 659 participants). Continuing or stopping antiplatelets probably makes little or no difference to incidences of bleeding serious enough to need a blood transfusion during or immediately after surgery (4 studies, 368 participants), and may make little or no difference to the number of ischaemic events [7].
Antiplatelet reversal for patients taking ticagrelor
Intravenous infusion